As Revlimid sales fall, Bristol Myers turns to its next multiple myeloma pill that's a molecular glue
An experimental pill developed by Bristol Myers Squibb has shown promising efficacy in a clinical trial for advanced multiple myeloma patients who have exhausted most other options. The drug, mezigdomide, is in a class of medicines called “molecular glues” that has seen substantial Big Pharma and VC investment in recent years.
In a Phase II study with 101 patients, 41% saw their cancers respond to mezigdomide plus dexamethasone. For those patients who responded, the duration of response was 7.6 months. All in all, patients did not see their cancers progress for a median of 4.4 months.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.